Telomir Pharmaceuticals (NASDAQ:TELO) Trading Down 3.4% – Here’s Why

Shares of Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) traded down 3.4% on Tuesday . The stock traded as low as $1.13 and last traded at $1.13. 27,578 shares were traded during trading, a decline of 74% from the average session volume of 104,128 shares. The stock had previously closed at $1.17.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Telomir Pharmaceuticals in a report on Friday, July 17th. One investment analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold”.

Telomir Pharmaceuticals Stock Performance

The stock’s fifty day moving average is $1.22 and its two-hundred day moving average is $1.26. The firm has a market cap of $72.22 million, a price-to-earnings ratio of -3.62 and a beta of -0.24.

Telomir Pharmaceuticals (NASDAQ:TELO) last issued its quarterly earnings data on Thursday, August 13th. The company reported ($0.79) earnings per share (EPS) for the quarter.

Institutional Investors Weigh In On Telomir Pharmaceuticals

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Bank of America Corp DE increased its stake in Telomir Pharmaceuticals by 283.9% during the 4th quarter. Bank of America Corp DE now owns 14,713 shares of the company’s stock valued at $61,000 after buying an additional 10,880 shares during the period. Marshall Wace LLP acquired a new stake in shares of Telomir Pharmaceuticals in the 2nd quarter worth approximately $95,000. Qube Research & Technologies Ltd acquired a new stake in shares of Telomir Pharmaceuticals in the 2nd quarter worth approximately $33,000. Jane Street Group LLC bought a new position in shares of Telomir Pharmaceuticals in the second quarter valued at approximately $62,000. Finally, Raymond James Financial Inc. boosted its holdings in shares of Telomir Pharmaceuticals by 4,101.9% in the third quarter. Raymond James Financial Inc. now owns 75,340 shares of the company’s stock valued at $105,000 after acquiring an additional 73,547 shares in the last quarter.

Telomir Pharmaceuticals Company Profile

Telomir Pharmaceuticals, Inc (NASDAQ: TELO) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel small-molecule therapies for cardiometabolic and fibrotic diseases. Leveraging a proprietary target discovery platform, the company aims to identify and modulate key biological pathways implicated in tissue fibrosis, inflammation and metabolic dysregulation. Its research strategy centers on oral agents intended to address high-unmet-need conditions such as nonalcoholic steatohepatitis (NASH) and systemic fibrotic disorders, where existing treatment options are limited.

The company’s lead development candidate is an oral inhibitor currently in early-phase clinical trials that targets growth factors involved in fibrotic tissue remodeling.